Satellos is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Satellos was founded on the discovery that dysregulated muscle stem-cell polarity - a process that balances replenishment of muscle stem cells and production of specialized tissue cells- can lead to the inability of the body to properly repair and regenerate muscle throughout life. Satellos' lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease. Satellos believes defects in muscle regeneration play a critical underlying role in numerous muscle disorders spanning rare diseases through to mass market indications. Accordingly, Satellos applies its proprietary discovery platform, MyoReGenX, to identify regulatory pathways and drug candidates to treat muscle disorders where stem cell polarity is dysregulated.
Company Details
- Employees
- 25
- Founded
- -
- Address
- Toronto, Ontario, Ca
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.satellos.com
- HQ
- Toronto, Ontario
Satellos Bioscience Questions
Satellos Bioscience's website is http://www.satellos.com
Satellos Bioscience's LinkedIn profile is https://ca.linkedin.com/company/satellos-bio
Satellos Bioscience has
25 employees.
View email and phone details for 25
employees at Satellos Bioscience.
Satellos Bioscience's industry is
Biotechnology Research
Satellos Bioscience's top competitors are
Bluerock Therapeutics,
Ccrm,
Vasomune Therapeutics, Inc.,
Omniabio,
Medicenna Therapeutics Corp.,
Bloom Burton & Co.,
Fable Therapeutics,
Appili Therapeutics,
Triumvira Immunologics, Inc.,
Dyne Therapeutics.
Satellos Bioscience's categories are Biotechnology Research
Satellos Bioscience's founding year is 2018
